ASCO Updates Breast Cancer Follow-Up Guidelines With Risk-Based Surveillance Approach
RICE Study: Can Immune Checkpoint Inhibitors Be Used Again After Progression?
Vincent Rajkumar: Limited Duration of Lenalidomide Maintenance is Just as Good as Indefinite Therapy
Tucatinib Plus Trastuzumab Deruxtecan Shows Activity but No Clear Added Benefit in HER2+ Advanced Breast Cancer
Durvalumab With Radiation Shows Promise in Chemotherapy-Ineligible Locally Advanced NSCLC
The Thirteen-Minute Infusion: What Sarclisa's Wearable Injector Signals for Cancer Care
The System Behind Access of New Cancer Drugs | Lisa Thompson Smith
Lovett Evan Reddick: Honored to Join GSK as Executive Director, Emerging Therapeutic Areas
